Stakeholder Value Corporate Governance

Investor Relations.

Driving sustainable, long-term growth through rigorous bioscience innovation, operational efficiency, and strategic global expansion.

22%

Driven by expanded distribution networks in the Middle East and increased B2B clinical partnerships.

18%

Percentage of gross profit allocated directly to our Kerala laboratories for new formulation development.

Zero

Maintaining a highly liquid and agile balance sheet to capitalize on emerging market opportunities.

Financial Reports & Filings

Stakeholder Communications

Strategic Inquiries

For inquiries regarding institutional investment, private equity, or corporate acquisitions, please contact our executive team directly.

Schedule a Briefing